Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease

Stefanie T. Jost; Veerle Visser-Vandewalle; Alexandra Rizos; Philipp A. Loehrer; Monty Silverdale; Julian Evans; Michael Samuel; Jan Niklas Petry-Schmelzer; Anna Sauerbier; Alexandra Gronostay; Michael T. Barbe; Gereon R. Fink; Keyoumars Ashkan; Angelo Antonini; Pablo Martinez-Martin; K. Ray Chaudhuri; Lars Timmermann; Haidar S. Dafsari; Roongroj Bhidayasiri; Cristian Falup-Pecurariu; Beomseok Jeon; Valentina Leta; Per Borghammer; Per Odin; Anette Schrag; Alexander Storch; Mayela Rodriguez Violante; Daniel Weintraub; Charles Adler; Paolo Barone; David J. Brooks; Richard Brown; Marc Cantillon; Camille Carroll; Miguel Coelho; Tove Henriksen; Michele Hu; Peter Jenner; Milica Kramberger; Padma Kumar; Mónica Kurtis; Simon Lewis; Irene Litvan; Kelly Lyons; Davide Martino; Mario Masellis; Hideki Mochizuki; James F. Morley; Melissa Nirenberg; Javier Pagonabarraga; J Panicker; N Pavese; E Pekkonen; R Postuma; R Rosales; A Schapira; T Simuni; F Stocchi; I Subramanian; M Tagliati; M Tinazzi; J Toledo; Y Tsuboi; R Walker

doi:10.1038/s41531-021-00174-x

Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease

Stefanie T. Jost^*, Veerle Visser-Vandewalle, Alexandra Rizos, Philipp A. Loehrer, Monty Silverdale, Julian Evans, Michael Samuel, Jan Niklas Petry-Schmelzer, Anna Sauerbier, Alexandra Gronostay, Michael T. Barbe, Gereon R. Fink, Keyoumars Ashkan, Angelo Antonini, Pablo Martinez-Martin, K. Ray Chaudhuri, Lars Timmermann, Haidar S. Dafsari^*, Roongroj Bhidayasiri, Cristian Falup-PecurariuBeomseok Jeon, Valentina Leta, Per Borghammer, Per Odin, Anette Schrag, Alexander Storch, Mayela Rodriguez Violante, Daniel Weintraub, Charles Adler, Paolo Barone, David J. Brooks, Richard Brown, Marc Cantillon, Camille Carroll, Miguel Coelho, Tove Henriksen, Michele Hu, Peter Jenner, Milica Kramberger, Padma Kumar, Mónica Kurtis, Simon Lewis, Irene Litvan, Kelly Lyons, Davide Martino, Mario Masellis, Hideki Mochizuki, James F. Morley, Melissa Nirenberg, Javier Pagonabarraga, J Panicker, N Pavese, E Pekkonen, R Postuma, R Rosales, A Schapira, T Simuni, F Stocchi, I Subramanian, M Tagliati, M Tinazzi, J Toledo, Y Tsuboi, R Walker

^*Corresponding author for this work

Peninsula Medical School

Research output: Contribution to journal › Article › peer-review

9 Downloads (Pure)

Abstract

AbstractTo identify predictors of 36-month follow-up quality of life (QoL) outcome after bilateral subthalamic nucleus deep brain stimulation (STN-DBS) in Parkinson’s disease (PD). In this ongoing, prospective, multicenter international study (Cologne, Manchester, London) including 73 patients undergoing STN-DBS, we assessed the following scales preoperatively and at 6-month and 36-month follow-up: PD Questionnaire-8 (PDQ-8), NMSScale (NMSS), Scales for Outcomes in PD (SCOPA)-motor examination, -activities of daily living, and -complications, and levodopa equivalent daily dose (LEDD). We analyzed factors associated with QoL improvement at 36-month follow-up based on (1) correlations between baseline test scores and QoL improvement, (2) step-wise linear regressions with baseline test scores as independent and QoL improvement as dependent variables, (3) logistic regressions and receiver operating characteristic curves using a dichotomized variable “QoL responders”/“non-responders”. At both follow-ups, NMSS total score, SCOPA-motor examination, and -complications improved and LEDD was reduced significantly. PDQ-8 improved at 6-month follow-up with subsequent decrements in gains at 36-month follow-up when 61.6% of patients were categorized as “QoL non-responders”. Correlations, linear, and logistic regression analyses found greater PDQ-8 improvements in patients with younger age, worse PDQ-8, and worse specific NMS at baseline, such as ‘difficulties experiencing pleasure’ and ‘problems sustaining concentration’. Baseline SCOPA scores were not associated with PDQ-8 changes. Our results provide evidence that 36-month QoL changes depend on baseline neuropsychological and neuropsychiatric non-motor symptoms burden. These findings highlight the need for an assessment of a wide range of non-motor and motor symptoms when advising and selecting individuals for DBS therapy.

Original language	English
Number of pages	0
Journal	Parkinson's Disease
Volume	7
Issue number	1
Early online date	8 Jun 2021
DOIs	https://doi.org/10.1038/s41531-021-00174-x
Publication status	Published - 8 Jun 2021

Access to Document

10.1038/s41531-021-00174-x

Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease

Cite this

Jost, S. T., Visser-Vandewalle, V., Rizos, A., Loehrer, P. A., Silverdale, M., Evans, J., Samuel, M., Petry-Schmelzer, J. N., Sauerbier, A., Gronostay, A., Barbe, M. T., Fink, G. R., Ashkan, K., Antonini, A., Martinez-Martin, P., Chaudhuri, K. R., Timmermann, L., Dafsari, H. S., Bhidayasiri, R., ... Walker, R. (2021). Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease. Parkinson's Disease, 7(1). https://doi.org/10.1038/s41531-021-00174-x

@article{dc5e4f0261c64e1aa9b8555db93038c5,

title = "Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease",

abstract = "AbstractTo identify predictors of 36-month follow-up quality of life (QoL) outcome after bilateral subthalamic nucleus deep brain stimulation (STN-DBS) in Parkinson{\textquoteright}s disease (PD). In this ongoing, prospective, multicenter international study (Cologne, Manchester, London) including 73 patients undergoing STN-DBS, we assessed the following scales preoperatively and at 6-month and 36-month follow-up: PD Questionnaire-8 (PDQ-8), NMSScale (NMSS), Scales for Outcomes in PD (SCOPA)-motor examination, -activities of daily living, and -complications, and levodopa equivalent daily dose (LEDD). We analyzed factors associated with QoL improvement at 36-month follow-up based on (1) correlations between baseline test scores and QoL improvement, (2) step-wise linear regressions with baseline test scores as independent and QoL improvement as dependent variables, (3) logistic regressions and receiver operating characteristic curves using a dichotomized variable “QoL responders”/“non-responders”. At both follow-ups, NMSS total score, SCOPA-motor examination, and -complications improved and LEDD was reduced significantly. PDQ-8 improved at 6-month follow-up with subsequent decrements in gains at 36-month follow-up when 61.6\% of patients were categorized as “QoL non-responders”. Correlations, linear, and logistic regression analyses found greater PDQ-8 improvements in patients with younger age, worse PDQ-8, and worse specific NMS at baseline, such as {\textquoteleft}difficulties experiencing pleasure{\textquoteright} and {\textquoteleft}problems sustaining concentration{\textquoteright}. Baseline SCOPA scores were not associated with PDQ-8 changes. Our results provide evidence that 36-month QoL changes depend on baseline neuropsychological and neuropsychiatric non-motor symptoms burden. These findings highlight the need for an assessment of a wide range of non-motor and motor symptoms when advising and selecting individuals for DBS therapy.",

author = "Jost, \{Stefanie T.\} and Veerle Visser-Vandewalle and Alexandra Rizos and Loehrer, \{Philipp A.\} and Monty Silverdale and Julian Evans and Michael Samuel and Petry-Schmelzer, \{Jan Niklas\} and Anna Sauerbier and Alexandra Gronostay and Barbe, \{Michael T.\} and Fink, \{Gereon R.\} and Keyoumars Ashkan and Angelo Antonini and Pablo Martinez-Martin and Chaudhuri, \{K. Ray\} and Lars Timmermann and Dafsari, \{Haidar S.\} and Roongroj Bhidayasiri and Cristian Falup-Pecurariu and Beomseok Jeon and Valentina Leta and Per Borghammer and Per Odin and Anette Schrag and Alexander Storch and Violante, \{Mayela Rodriguez\} and Daniel Weintraub and Charles Adler and Paolo Barone and Brooks, \{David J.\} and Richard Brown and Marc Cantillon and Camille Carroll and Miguel Coelho and Tove Henriksen and Michele Hu and Peter Jenner and Milica Kramberger and Padma Kumar and M{\'o}nica Kurtis and Simon Lewis and Irene Litvan and Kelly Lyons and Davide Martino and Mario Masellis and Hideki Mochizuki and Morley, \{James F.\} and Melissa Nirenberg and Javier Pagonabarraga and J Panicker and N Pavese and E Pekkonen and R Postuma and R Rosales and A Schapira and T Simuni and F Stocchi and I Subramanian and M Tagliati and M Tinazzi and J Toledo and Y Tsuboi and R Walker",

year = "2021",

month = jun,

day = "8",

doi = "10.1038/s41531-021-00174-x",

language = "English",

volume = "7",

journal = "Parkinson's Disease",

issn = "2090-8083",

publisher = "John Wiley and Sons Ltd",

number = "1",

}

Jost, ST, Visser-Vandewalle, V, Rizos, A, Loehrer, PA, Silverdale, M, Evans, J, Samuel, M, Petry-Schmelzer, JN, Sauerbier, A, Gronostay, A, Barbe, MT, Fink, GR, Ashkan, K, Antonini, A, Martinez-Martin, P, Chaudhuri, KR, Timmermann, L, Dafsari, HS, Bhidayasiri, R, Falup-Pecurariu, C, Jeon, B, Leta, V, Borghammer, P, Odin, P, Schrag, A, Storch, A, Violante, MR, Weintraub, D, Adler, C, Barone, P, Brooks, DJ, Brown, R, Cantillon, M, Carroll, C, Coelho, M, Henriksen, T, Hu, M, Jenner, P, Kramberger, M, Kumar, P, Kurtis, M, Lewis, S, Litvan, I, Lyons, K, Martino, D, Masellis, M, Mochizuki, H, Morley, JF, Nirenberg, M, Pagonabarraga, J, Panicker, J, Pavese, N, Pekkonen, E, Postuma, R, Rosales, R, Schapira, A, Simuni, T, Stocchi, F, Subramanian, I, Tagliati, M, Tinazzi, M, Toledo, J, Tsuboi, Y & Walker, R 2021, 'Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease', Parkinson's Disease, vol. 7, no. 1. https://doi.org/10.1038/s41531-021-00174-x

TY - JOUR

T1 - Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease

AU - Jost, Stefanie T.

AU - Visser-Vandewalle, Veerle

AU - Rizos, Alexandra

AU - Loehrer, Philipp A.

AU - Silverdale, Monty

AU - Evans, Julian

AU - Samuel, Michael

AU - Petry-Schmelzer, Jan Niklas

AU - Sauerbier, Anna

AU - Gronostay, Alexandra

AU - Barbe, Michael T.

AU - Fink, Gereon R.

AU - Ashkan, Keyoumars

AU - Antonini, Angelo

AU - Martinez-Martin, Pablo

AU - Chaudhuri, K. Ray

AU - Timmermann, Lars

AU - Dafsari, Haidar S.

AU - Bhidayasiri, Roongroj

AU - Falup-Pecurariu, Cristian

AU - Jeon, Beomseok

AU - Leta, Valentina

AU - Borghammer, Per

AU - Odin, Per

AU - Schrag, Anette

AU - Storch, Alexander

AU - Violante, Mayela Rodriguez

AU - Weintraub, Daniel

AU - Adler, Charles

AU - Barone, Paolo

AU - Brooks, David J.

AU - Brown, Richard

AU - Cantillon, Marc

AU - Carroll, Camille

AU - Coelho, Miguel

AU - Henriksen, Tove

AU - Hu, Michele

AU - Jenner, Peter

AU - Kramberger, Milica

AU - Kumar, Padma

AU - Kurtis, Mónica

AU - Lewis, Simon

AU - Litvan, Irene

AU - Lyons, Kelly

AU - Martino, Davide

AU - Masellis, Mario

AU - Mochizuki, Hideki

AU - Morley, James F.

AU - Nirenberg, Melissa

AU - Pagonabarraga, Javier

AU - Panicker, J

AU - Pavese, N

AU - Pekkonen, E

AU - Postuma, R

AU - Rosales, R

AU - Schapira, A

AU - Simuni, T

AU - Stocchi, F

AU - Subramanian, I

AU - Tagliati, M

AU - Tinazzi, M

AU - Toledo, J

AU - Tsuboi, Y

AU - Walker, R

PY - 2021/6/8

Y1 - 2021/6/8

N2 - AbstractTo identify predictors of 36-month follow-up quality of life (QoL) outcome after bilateral subthalamic nucleus deep brain stimulation (STN-DBS) in Parkinson’s disease (PD). In this ongoing, prospective, multicenter international study (Cologne, Manchester, London) including 73 patients undergoing STN-DBS, we assessed the following scales preoperatively and at 6-month and 36-month follow-up: PD Questionnaire-8 (PDQ-8), NMSScale (NMSS), Scales for Outcomes in PD (SCOPA)-motor examination, -activities of daily living, and -complications, and levodopa equivalent daily dose (LEDD). We analyzed factors associated with QoL improvement at 36-month follow-up based on (1) correlations between baseline test scores and QoL improvement, (2) step-wise linear regressions with baseline test scores as independent and QoL improvement as dependent variables, (3) logistic regressions and receiver operating characteristic curves using a dichotomized variable “QoL responders”/“non-responders”. At both follow-ups, NMSS total score, SCOPA-motor examination, and -complications improved and LEDD was reduced significantly. PDQ-8 improved at 6-month follow-up with subsequent decrements in gains at 36-month follow-up when 61.6% of patients were categorized as “QoL non-responders”. Correlations, linear, and logistic regression analyses found greater PDQ-8 improvements in patients with younger age, worse PDQ-8, and worse specific NMS at baseline, such as ‘difficulties experiencing pleasure’ and ‘problems sustaining concentration’. Baseline SCOPA scores were not associated with PDQ-8 changes. Our results provide evidence that 36-month QoL changes depend on baseline neuropsychological and neuropsychiatric non-motor symptoms burden. These findings highlight the need for an assessment of a wide range of non-motor and motor symptoms when advising and selecting individuals for DBS therapy.

AB - AbstractTo identify predictors of 36-month follow-up quality of life (QoL) outcome after bilateral subthalamic nucleus deep brain stimulation (STN-DBS) in Parkinson’s disease (PD). In this ongoing, prospective, multicenter international study (Cologne, Manchester, London) including 73 patients undergoing STN-DBS, we assessed the following scales preoperatively and at 6-month and 36-month follow-up: PD Questionnaire-8 (PDQ-8), NMSScale (NMSS), Scales for Outcomes in PD (SCOPA)-motor examination, -activities of daily living, and -complications, and levodopa equivalent daily dose (LEDD). We analyzed factors associated with QoL improvement at 36-month follow-up based on (1) correlations between baseline test scores and QoL improvement, (2) step-wise linear regressions with baseline test scores as independent and QoL improvement as dependent variables, (3) logistic regressions and receiver operating characteristic curves using a dichotomized variable “QoL responders”/“non-responders”. At both follow-ups, NMSS total score, SCOPA-motor examination, and -complications improved and LEDD was reduced significantly. PDQ-8 improved at 6-month follow-up with subsequent decrements in gains at 36-month follow-up when 61.6% of patients were categorized as “QoL non-responders”. Correlations, linear, and logistic regression analyses found greater PDQ-8 improvements in patients with younger age, worse PDQ-8, and worse specific NMS at baseline, such as ‘difficulties experiencing pleasure’ and ‘problems sustaining concentration’. Baseline SCOPA scores were not associated with PDQ-8 changes. Our results provide evidence that 36-month QoL changes depend on baseline neuropsychological and neuropsychiatric non-motor symptoms burden. These findings highlight the need for an assessment of a wide range of non-motor and motor symptoms when advising and selecting individuals for DBS therapy.

UR - https://pearl.plymouth.ac.uk/pms-research/265/

U2 - 10.1038/s41531-021-00174-x

DO - 10.1038/s41531-021-00174-x

M3 - Article

SN - 2090-8083

VL - 7

JO - Parkinson's Disease

JF - Parkinson's Disease

IS - 1

ER -

Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease

Abstract

Access to Document

Other files and links

Fingerprint

Cite this